Analysts Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $10.20

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.20.

PALI has been the topic of a number of recent research reports. HC Wainwright initiated coverage on Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 price target on the stock. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus initiated coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock.

Hedge Funds Weigh In On Palisade Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in PALI. Cetera Investment Advisers bought a new stake in Palisade Bio during the fourth quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in Palisade Bio during the fourth quarter valued at about $26,000. Virtu Financial LLC bought a new stake in Palisade Bio during the fourth quarter valued at about $28,000. Atom Investors LP bought a new stake in Palisade Bio during the fourth quarter valued at about $33,000. Finally, Barclays PLC bought a new stake in Palisade Bio during the fourth quarter valued at about $35,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Stock Down 1.0%

PALI stock opened at $1.92 on Wednesday. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.86. The business’s fifty day simple moving average is $1.98 and its two-hundred day simple moving average is $1.92. The firm has a market cap of $321.45 million, a price-to-earnings ratio of -0.91 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Research analysts expect that Palisade Bio will post -0.18 EPS for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.